Klass Bakker, MD, PhD, was appointed as the new CMO of pharmaceutical company Oncopeptides.
Four things to know:
1. Dr. Klaas is a board-certified neurosurgeon from the University of Groningen in the Netherlands.
2. Oncopeptides focuses on the development of therapies for hematological cancers.
3. Dr. Klaas has a PhD in immune-hematology and has authored over 40 publications in international peer-reviewed journals.
4. He replaces Johan Harmenberg as CMO, who will remain as a member of the company's medical team.